Tavegil1 mg/ml 2 ml, 5 pcs.

Pharmacodynamics

H 1 is a histaminoblocker – ethanolamine derivative.

Action

Antipruritic, anti-allergic. Reduces vascular permeability. It has a sedative and M-cholinoblocking effect. Does not have sleeping activity.

Prevents the development of vasodilation and smooth muscle contraction induced by histamine. Reduces capillary permeability. Inhibits exudation and formation of edema, reduces itching.

The antihistamine activity of the drug reaches its maximum in 5-7 hours, lasts for 10-12 hours and in some cases up to 24 hours.

Indications

– prevention or treatment of allergic and pseudo-allergic reactions (including with the administration of contrast agents, blood transfusions, diagnostic use of histamine);

– angioedema, anaphylactic or anaphylactoid shock (as an additional remedy).

Pharmacological effect

Pharmacodynamics

H 1 – histamine blocker – ethanolamine derivative.

Action

Antipruritic, antiallergic. Reduces vascular permeability. Has a sedative and M-anticholinergic effect. Does not have hypnotic activity.

Prevents the development of vasodilation and contraction of smooth muscles induced by histamine. Reduces capillary permeability. Inhibits exudation and the formation of edema, reduces itching.

The antihistamine activity of the drug reaches its maximum after 5-7 hours, persists for 10-12 hours, and in some cases up to 24 hours.

Special instructions

Those taking Tavegil are advised to refrain from driving vehicles, operating machinery, and other activities that require increased attention.

Active ingredient

Clemastine

Composition

Active ingredient:

2 mg clemastine.

Pregnancy

The use of the drug during pregnancy and breastfeeding is contraindicated.

Contraindications

Hypersensitivity;
taking MAO inhibitors;
diseases of the lower respiratory tract (including bronchial asthma);
tavegil should not be used in women during breastfeeding;
tavegil in tablet form should not be used in children under 6 years of age.

With caution:

in patients with stenosing gastric ulcer; pyloroduodenal obstruction; with obstruction of the bladder neck; prostatic hypertrophy, accompanied by urinary retention; with increased intraocular pressure; hyperthyroidism; diseases of the cardiovascular system, including arterial hypertension.

Side Effects

Classification of the frequency of adverse reactions: very often (>1/10); often (>1/100, 1/1000, 1/10,000, <1/1000); very rare (<1/10,000).From the nervous system: often – increased fatigue, drowsiness, sedation, weakness, feeling tired, lethargy, impaired coordination of movements; infrequently – dizziness; rarely – headache, tremor, stimulating effect.From the gastrointestinal tract: rarely – dyspepsia, nausea, vomiting, gastralgia, dry mouth; very rarely – constipation.From the senses: rarely – impaired clarity of visual perception, diplopia, acute labyrinthitis, tinnitus.From the kidneys and urinary tract: very rarely – frequent or difficult urination.From the respiratory system: rarely – thickening of bronchial secretions and difficulty in sputum discharge, a feeling of pressure in the chest, breathing problems, nasal congestion.From the cardiovascular system: rarely – decreased blood pressure (more often in elderly patients), extrasystole; very rarely – tachycardia.From the blood and hematopoietic organs: rarely – hemolytic anemia, thrombocytopenia, agranulocytosis.From the skin and subcutaneous fat: rarely – skin rash.From the immune system: infrequently – photosensitivity, shortness of breath; rarely – anaphylactic shock.If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Tavegil® enhances the effect of drugs that depress the central nervous system (hypnotics, sedatives, anxiolytics), m-anticholinergics, and alcohol.

Incompatible with simultaneous use of MAO inhibitors.

Overdose

Symptoms. An overdose of antihistamines can lead to both depressant and stimulating effects on the central nervous system, more often observed in children.

Clinical pharmacology

Communication with plasma proteins is 95%. Elimination from plasma is biphasic, the corresponding T1/2 are 3.6 ± 0.9 hours and 37 ± 16 hours.

Clemastine undergoes significant metabolism in the liver. Metabolites are mainly (45-65%) excreted through the kidneys in the urine; unchanged active substance is found in urine only in trace amounts.

During lactation, small amounts of clemastine may pass into breast milk.

Short product description

Tavegil is a first generation antihistamine.
Active ingredient: clemastine hydrofumarate *.
Available in ampoules and tablets (10 and 20 pieces).
* Instructions for medical use, RU P N008878/02 dated 06/02/2010

Storage conditions

Store out of the reach of children at a temperature of 15° to 30°C.

Shelf life

5 years.

Manufacturer

Takeda Austria GmbH, Austria